Imugene Limited

ASX:IMU ISIN:AU000000IMU9

Imugene Limited ASX IMUImugene Limited (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

 
    
        

Lihat di Bahasa Lain

Berita

Laporan Pasar Australia 16 September 2010: Conquest Mining Limited (ASX:CQT) memulai Kontrak Pengambilan Emas-Perak-Tembaga dengan Shandong Guoda Gold

🕔9/16/2010 1:30:08 PM 15435

Laporan Pasar Australia 16 September 2010 memuat; Conquest Mining Limited (ASX:CQT) telah memulai kontrak pengambilan kandungan untuk penjualan kandungan emas-perak dan tembaga dari cadangan V2 pada Proyek Mt Carlton,Heemskirk Consolidated Limited (ASX:HSK) telah mengumumkan penanda tanganan persetujuan dengan Conquest Mining Limited (ASX:CQT), Imugene Limited (ASX:IMU) hari ini telah mengumumkan bahwa mereka telah berhasil menyelesaikan uji coba kedua untuk Vaksin Porcine Reproductive and Respiratory Syndrome (PRRS) dan Synthesis Energy Systems Inc. (NASDAQ:SYMX) dan Coalworks Limited (ASX:CWK) hari ini menampilkan presentasi bersama yang bertema “Produksi Bahan Bakar Cair dari Oaklands Coal Utilizing U-GAS (R) dan MTG Technologies”.

Baca Full Story
###

82,472 TAMPILAN PROFIL PERUSAHAAN

  • Halaman ini dilihat: (7 Hari Terakhir: 19) (30 Hari Terakhir: 77) (Sejak Ditampilkan: 8220) 

Data Perusahaan

    Markas Besar
  • Suite 1, 1233 High Street
    Armadale, VIC 3143
    Australia
  • Telepon
  • +61-3-9824-5254 
  • Fax
  • +61-3-9822-7735 
  • Sektor Utama
  • Kesehatan & Pharm 
  • Industri Utama
  • Biotechnology 
  • Homepage
  • www.imugene.com

Lebih banyak Berita lagi

  • 2025/04/03: 1st dose level cleared IV combination arm onCARlytics trial*
  • 2025/03/19: Azer-cel Granted FDA Fast Track Designation in Blood Cancer*
  • 2025/03/13: Application for quotation of securities - IMU*
  • 2025/03/04: Darren Keamy Appointed CFO and Company Secretary*
  • 2025/02/28: Half Yearly Report and Accounts*
  • 2025/02/27: Imugene Granted India Patent for Oncolytic Virotherapy CF33*
  • 2025/02/26: Imugene OnCARlytics Patent Allowance in China*
  • 2025/02/21: Change of Directors Interest Notice x 5*
  • 2025/02/21: Notification regarding unquoted securities - IMU*
  • 2025/02/21: Application for quotation of securities - IMU*
*refer to company website

Media sosial